Ulinastatin Market Size, Share, Growth, and Industry Analysis, By Type (Powder and Injection), By Application (Sepsis, Acute Pancreatitis and Others), Regional Insights, and Forecast To 2033

• 

   Request a Free Sample To Get More Information on this Market

ULINASTATIN MARKET REPORT OVERVIEW

Global Ulinastatin Market size was USD 0.35 Billion in 2024 and market is projected to touch USD 1.32 Billion by 2033, exhibiting a CAGR of 15.74% during the forecast period.

Ulinastatin is a glycoprotein with a molecular weight of 25–40 kDa that is extracted from healthy human urine or synthesized synthetically and functions as a urinary trypsin inhibitor (UTI). Clinical applications of highly pure ulinastatin include the management of burns, septic shock, toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, acute and chronic pancreatitis, and Stevens-Johnson syndrome. The medication is utilised in South Korea, China, India, and Japan, where it is sold under the trade name Miraclid. It is sold under the brand names Ulihope, Ulicrit-Liquid, Ulinase, and U-Tryp in India, where it is approved for the treatment of acute pancreatitis and severe sepsis. Other names for it include Bikunin and Urinastatin. It is sold in China under the trade name Techpool Roan and is approved for the treatment of acute pancreatitis, chronic recurrent pancreatitis, and acute circulatory failure.

COVID-19 IMPACT

"Decline in Sales Due to Lockdowns to Hinder Market Growth"

The COVID-19 pandemic had a significant impact on several nations, which had a negative impact on regional market expansion. Governments in this region did, however, start widespread immunisation campaigns in the first half of 2021, which led to the restart of the production of additional medicines than COVID-19 vaccines and related items. In turn, this will fuel the expansion of the plasma protease c1 inhibitor market over the forecast period.

Market vendors should concentrate more on the growth prospects in the fast-growing segments while preserving their positions in the slow-growing segments in order to take advantage of the chances and recover from the post COVID-19 impact. The market forecast study for plasma protease C1 inhibitors provides in-depth details on the major vendor profiles. The profiles provide details on the leading companies' production, sustainability, and future prospects.

LATEST TRENDS

"Treatment of Sepsis to Attract Customers and Enhance Market Growth"

Sepsis has been treated with ulinastatin. The amount of any change in outcomes to direct future decision-making, however, is in question. Evaluation of ulinastatin's effects on mortality and associated outcomes in sepsis patients is the goal. Methods: 13 randomised controlled trials and 2 prospective studies with 1358 patients with sepsis, severe sepsis, or septic. PubMed, Medline, Embase, and China National Knowledge Infrastructure (CNKI) for Chinese Technical Periodicals were the electronic databases searched for this study.

ULINASTATIN MARKET SEGMENTATION

By Type Analysis

Based on type market is classified as powder and injection.

By Application Analysis

Based on application market is classified as sepsis, acute pancreatitis and others.

DRIVING FACTORS

"Selective Antagonists to Uplift Market Profile"

One of the major plasma proteases C1 inhibitor market trends that is fostering market expansion is the rise of bradykinin B2 receptor antagonists. The acute episodes of swelling and inflammation in hereditary angioedema are treated with an antagonist of the bradykinin B2 receptor. For instance, Icatibant (Firazyr), a selective antagonist of the bradykinin B2 receptor, has been licenced by the US Food and Drug Administration (FDA) for the treatment of acute episodes of HAE in adults.

"Increased Research and Development to Augment Market Growth"

One of the main factors propelling the plasma protease c1 inhibitor market's expansion is an increase in research and development. The growing focus of biopharmaceutical companies on developing efficient plasma protease C1 inhibitor treatment drugs/therapy for various health problems, such as HAE, diabetic macular edoema (DME), and others, is expected to boost the global plasma protease C1 inhibitor market. There are currently several kallikrein inhibitor drugs in preclinical and clinical development.

RESTRAINING FACTORS

"High Cost and Complicated Therapy to Impede Market Growth"

One of the things preventing the plasma protease c1 inhibitor market from expanding is the high cost and complicated therapy. Blood-borne illnesses like the human immunodeficiency virus (HIV), hepatitis B, and hepatitis C transmission have been related to plasma-based medications. The danger of infection transmission during transfusion persists despite primary blood screening being carried out. This is brought on by the presence of different pathogen strains, diseases that can survive blood purification, and the danger posed by emerging viruses like flaviviruses.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

ULINASTATIN MARKET REGIONAL INSIGHTS

"North America to Dominate the Market Due to Established Healthcare Infrastructure"

Over the course of the forecast period, the ulinastatin market will expand in North America due to the region's established healthcare infrastructure and notable market players who provide patients suffering from HAE viable treatment options. In order to help vendors, create effective business plans, this market research report includes comprehensive information on the competition intelligence, marketing gaps, and geographical prospects available to them.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage"

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Top Ulinastatin Companies

• Han Lim Pharmaceutical (South Korea)
• Bharat Serums & Vaccines Ltd. (Altius) (India)
• Mochida Pharmaceuticals (Japan)
• Techpool (India)
• Lupin (Mumbai)

REPORT COVERAGE

The report anticipates a detailed analysis of the global market size at the regional and national level, the ssegmentation market growth and market share. The prime objective of the report is to help user understand the market in terms of definition, market potential, influencing trends, and the challenges faced by the market. Aanalysis of sales, the impact of the market players, recent developments, opportunity analysis, strategic market growth analysis, territorial market expansion, and technological innovations are the subject matter explained in the report.